Drugs / INF beta-1a
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03283397 Comparator | Mar 2019 → Jul 2023 | relapsing-remitting multiple sclerosis | Bosnalijek D.D | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INF beta-1a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03283397 ↗ |